Core Viewpoint - Haixi New Drug (02637.HK) has announced a delay in its Hong Kong listing originally scheduled for October 17, 2025, due to the need for additional time to finalize the announcement regarding the final offer price, international placement subscription levels, and other related information [2][3]. Group 1: Company Overview - Haixi New Drug was established in 2012 and is a commercial-stage pharmaceutical company that integrates research and development, production, and sales capabilities [3]. - The company has a diversified product portfolio, primarily consisting of generic drugs for digestive, cardiovascular, endocrine, neurological, and inflammatory diseases [3]. - As of September 30, 2025, Haixi New Drug has received approval from the National Medical Products Administration for 15 generic drugs, with four included in the national volume-based procurement program [3]. Group 2: IPO Details - The company plans to issue 11.5 million H-shares with an offer price range of HKD 69.88 to HKD 86.40, aiming to raise approximately HKD 8.04 billion to HKD 9.94 billion [4]. - The initial allocation ratio for the public offering is set at 10%, with the possibility of adjustment to a maximum of 15% [4]. - The listing market capitalization is estimated to be between HKD 55 billion and HKD 68 billion [4].
海西新药(02637)，宣布上市时间表顺延，原定今天香港上市